A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
NCT06158516
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Neuroendocrine Tumor
Interventions
DRUG:
Surufatinib
DRUG:
Placebo
Sponsor
Changhai Hospital